FDA pauses Novavax's trial of combo COVID-flu shot on safety concerns

The U.S. Food and Drug Administration has put Novavax's (NVAX.O), opens new tab trial of an experimental COVID-flu vaccine combination on hold after one person who received the shot reported nerve damage, the company said on Wednesday.